The integration of racial and gender variations in Cer profile into CVD management is essential, since increased susceptibility to diabetes and dyslipidemia in Asian males is an example that affects both risk and treatment response, including that to NSMase blockers or dietary interventions. This evidence concerns the gene SMPD2 and metabolic syndrome.